US Patent

US7807689 — Dipeptidyl peptidase inhibitors

Method of Use · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2028-06-27 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a compound and its pharmaceutical compositions, as well as methods of using them.

USPTO Abstract

The present invention provides a compound of the formula: or stereoisomers or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, articles of manufacture comprising the same, and methods of using the same.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1337 —
U-1337 —
U-1337 —
U-1337 — alogliptin-benzoate
U-1337 — alogliptin-benzoate
U-1337 —
U-1337 —
U-1337 —
U-1337 —
U-1337 — alogliptin-benzoate
U-1337 —

Patent Metadata

Patent number
US7807689
Jurisdiction
US
Classification
Method of Use
Expires
2028-06-27
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.